Mapatumumab: Completed Phase II enrollment

Human Genome completed enrollment of 111 patients in an open-label, U.S. and European Phase II trial evaluating carboplatin and paclitaxel with or without 10 or 30 mg/kg of intravenous HGS-ETR1 as fir...